ArticleFrontiers in nutrition2026
Alcalase-hydrolyzed casein peptides after simulated gastrointestinal digestion alleviate high-fat diet-induced metabolic dysfunction in mice.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: High-fat diet (HFD)-induced metabolic dysfunction is associated with disturbances in gut microbial composition and hepatic lipid metabolism. This study investigated the metabolic effects of Alcalase-hydrolyzed casein peptides after simulated gastrointestinal digestion (MCPs) in HFD-fed mice and explored their potential association with gut microbiota and fecal metabolic alterations. Results: MCP supplementation attenuated body weight gain, improved serum lipid profiles, and alleviated hepatic steatosis and injury in HFD-fed mice. In the colon, MCPs ameliorated histological damage and suppressed the mRNA and protein expression of pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α. Gut microbiota analysis revealed increased relative abundances of Conclusion: Collectively, MCPs may alleviate HFD-induced metabolic dysfunction by modulating gut microbiota-associated metabolic profiles and improving intestinal and hepatic metabolic responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.